Safety of continuative therapy with novel anticoagulants during cardiac rhythm devices implantation
Project Objectives
Study aims to compare incidence of bleeding complications (hematoma, pocket bleeding, reoperation) after procedures of cardiac rhythm devices implantation in patients taking novel oral anticoagulants (Dabigatran, Apixaban and Rivaroxaban; uninterrupted anticoagulation group) compared with those who promptly discontinued these drugs before intervention (discontinuation group).
Start and End Dates
Not yet started; waiting for Ethical Committee approval
Principal Investigator
- Dott. Danilo Ricciardi, Principal Investigator
- Prof. Germano Di Sciascio
Host Institution
Campus Bio-Medico University of Rome
